Latest News and Press Releases

- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...

i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed roundFunds will be used to accelerate a new generation of T cell therapies against solid tumors...

Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...

Lücke zwischen Grundlagenforschung und klinischer Anwendung schließenMehr als 50 Prozent aller geförderten Projekte erhalten Anschlussfinanzierung Bad Homburg v.d. Höhe, 23.04.2024 – Die...

Closing the gap between basic research and clinical applicationMore than 50 percent of all funded projects received follow-up funding Bad Homburg v.d. Höhe, Germany, April 23, 2024 - ForTra gGmbH...

Further expansion of management expertise to accelerate BellaSeno´s market entry Leipzig, Germany, April 3, 2024 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...

Die neuen Beiräte werden ihr Fachwissen in den Bereichen Immunologie, Pathologie, Entzündungsprozesse und in MetrioPharms Hauptindikation Duchenne-Muskeldystrophie einbringenDie Beiräte haben bereits...

The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy Advisors have previously collaborated with...

-- Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet -- Graft vascularization was achieved by embedding vascular pedicle into the scaffold ...